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Abstract
 
Recombinant porcine parvovirus virus-like particles (PPV-VLPs) are particulate exogenous anti-
gens that induce a strong, specific cytotoxic T lymphocyte (CTL) response in the absence of adju-
vant. In the present report, we demonstrate in vivo that dendritic cells (DCs) present PPV-VLPs
 
to CD8
 
  
 
T cells after intracellular processing. PPV-VLPs are captured by DCs with a high effi-
cacy, which results in the delivery of these exogenous antigens to 50% of the whole spleen DC
 
population. In vivo
 
,
 
 a few hours after injection, PPV-VLPs are presented exclusively to CD8
 
 
 
T cells by CD8
 
 
 
  
 
DCs, whereas 15 hours later they are presented mainly by CD8
 
 
 
  
 
DCs. Af-
ter PPV-VLPs processing, a fraction of CD11b
 
  
 
DCs undergo phenotypic changes, i.e., the
up-regulation of CD8
 
 
 
 and CD205 and the loss of CD4 molecules on their surface. The fail-
ure to detect mRNA coding for CD8
 
 
 
 in CD11b
 
  
 
DCs suggests that CD8
 
 
 
 expression by
these cells is not due to de novo synthesis. In recombination-activating gene knockout mice
 
(Rag
 
 
 
/
 
 
 
), CD11b
 
  
 
DCs did not express CD8
 
  
 
and PPV-VLPs presentation by CD8
 
 
 
  
 
DCs
 
was severely diminished. These results indicate that both CD8
 
 
 
  
 
and CD8
 
 
 
  
 
DCs play an im-
portant role in the induction of CTL responses by exogenous antigens, such as VLP.
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Introduction
 
The induction of CTL responses requires the presentation
of antigen-derived peptides associated to MHC class I mol-
ecules on the surface of APCs to specific CD8
 
  
 
T cells.
These peptides essentially derive from antigens processed in
the cytosol of APCs. Thus, antigens that do not reach the
cytosol of APCs should not elicit a CTL response. How-
ever, it is now well established that host APCs can process
exogenous cell-associated antigens and present them associ-
ated to MHC class I molecules through a process called
cross-priming (1, 2). In this process, cell-associated antigens
gain access to the MHC class I pathway by the transfer of
these antigens from cells that expressed or carried them to
APCs. Soluble exogenous antigens can also gain access to
the cytosol of APCs through an alternative pathway exclu-
 
sive for macrophage and dendritic cells (DCs)
 
* 
 
(3), al-
though cell-associated antigens are much more efficiently
presented than soluble antigens (4, 5). Both macrophages
(6) and DCs (7) have been reported to cross-present anti-
gens, but only DCs are able to stimulate naive CD8
 
  
 
T
cells (8). Two routes of cross-priming have been proposed.
One route involves the passage of antigens from endosomes
to cytosol and in the other route the antigens do not escape
from endosomes and are processed inside these vesicles (9).
The first route seems to be mostly used by DCs whereas
the second one is specific to macrophages (10).
DCs do not constitute a homogeneous cell population.
On the basis of the expression of CD8
 
 
 
 homodimer and
CD4 molecules, these three subpopulations of DCs have
been described in murine spleen: CD4
 
 
 
CD8
 
 
 
 
 
, CD4
 
 
 
CD8
 
 
 
  
 
(both are CD11b
 
high
 
), and CD8
 
 
 
 
 
CD11c
 
 
 
(CD11b
 
low
 
) (11, 12). However, so far the attention has
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Abbreviations used in this paper:
 
 
 
 
 
2M, 
 
 
 
2-microglobulin; DC, den-
dritic cell; LCMV, lymphocytic choriomeningitis virus; MACS, mag-
 
netic-activated cell sorting; OVA
 
257–264
 
, peptide corresponding to the se-
quence of amino acids 257–264 of the chicken egg albumin; PPV,
porcine parvovirus; PPV-VLPss-OVA, PPV virus-like particles carrying
OVA
 
257–264
 
; Rag, recombination-activating gene; RT, reverse transcrip-
tion; TAP, transporter associated with antigen processing; VLP, virus-
like particle; VP, viral protein. 
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been focused mainly on the study of CD8
 
 
 
  
 
and CD8
 
 
 
 
 
DCs, which until recently have been considered to be de-
rived from myeloid and lymphoid progenitors, respectively
(13, 14). It has recently been reported that CD8
 
 
 
  
 
but not
CD8
 
 
 
  
 
DCs can cross-prime CD8
 
  
 
T cells in vivo exclud-
ing a role for CD8
 
 
 
  
 
DCs in CTL induction (15).
Virus-like particles (VLPs) have clearly revealed an ex-
ceptional capacity to trigger CTL responses (3, 16–19).
However, the mechanisms of uptake, processing, and pre-
sentation of these exogenous particles remain unclear. In
particular, the APC involved in the induction of CTL re-
sponse by VLPs is still unknown. Indeed, DCs and mac-
rophages have been shown to be involved in the processing
of VLPs (16, 20–22), but no direct in vivo evidence has
been obtained identifying the APC that can uptake, pro-
cess, and present VLPs.
We have developed an antigen delivery system based on
nonreplicative, recombinant porcine parvovirus (PPV)-
VLPs formed by the self-assembly of the viral protein
(VP)2 of PPV (19, 23). The VP2 protein, the most abun-
dant structural VP of the PPV capsid (24) and carrying for-
eign CD8
 
 
 
 T cell epitopes, self-assembles into 25-nM
pseudo viral particles after expression in insect cells (19).
Mice immunized with these PPV-VLPs, carrying a CD8
 
 
 
T cell epitope from the lymphocytic choriomeningitis virus
(LCMV) nucleoprotein and in the absence of adjuvant, de-
veloped a CTL response against LCMV that protected
mice against a lethal intracerebral injection of LCMV based
on the induction of high frequency of CTLs of high avidity
(19, 25). This cytotoxic response was restricted to MHC
class I molecules and mediated by CD8
 
  
 
T cells (19).
We have studied the mechanisms of in vivo presentation
of particulate exogenous antigens using PPV-VLPs as a
model to determine whether particulate antigens can be
captured and processed directly by DCs or if they induce
CTL response by cross-priming after capture by other cells.
In this report, we demonstrate that PPV-VLPs target DCs
with a very high efficiency and directly induce a specific
CTL response without cross-priming. CD8
 
 
 
  
 
and CD8
 
 
 
 
 
DCs capture and process these particles. We also establish
that CD8
 
 
 
  
 
DCs play an important role in CTL induction
by these exogenous antigens. Furthermore, this study dem-
onstrates for the first time that stimulation by VLPs induces
phenotypic changes on CD8
 
 
 
  
 
DCs, which leads to the ac-
quisition of several surface molecules and the loss of others.
 
Materials and Methods
 
Mice.
 
6–8-wk-old female C57BL/6 (H-2
 
b
 
) mice were pur-
chased from Janvier. Transporter associated with antigen process-
ing (TAP)1 female knockout mice (TAP
 
 
 
/
 
 
 
) were a gift from A.
Bandeira (Institut Pasteur, Paris, France). Recombination-activat-
ing gene (Rag)2 knockout mice (Rag2
 
 
 
/
 
 
 
) and 
 
 
 
2-microglobu-
lin (
 
 
 
2M
 
 
 
/
 
 
 
)
 
 
 
knockout mice were obtained from the Centre de
Développement des Techniques Avancées pour l’Expérimenta-
tion Animale (Orléans, France). All animals were bred onto a
C57BL/6 background. The mice were maintained under specific
pathogen-free conditions.
 
PPV-VLPs.
 
The construction, characterization, and purifica-
tion of recombinant and control PPV-VLPs were previously de-
scribed in detail (19). In brief, the VP2 gene was expressed with
the 257–264 peptide plus natural flanking sequences (LEQLESI-
INFEKLTE) from chicken egg ovalbumin (OVA
 
257–264
 
) in its 5
 
 
 
end (PPV-VLPs carrying the OVA
 
257–264
 
 epitope [PPV-VLPs-
OVA]) or without this sequence (PPV-VLPs) using a baculovirus
vector system. After the infection of Sf9 insect cells, the recom-
binant VLPs were purified by salt precipitation with 20% am-
monium sulfate followed by dialysis. Characterization of PPV-
VLPs-OVA and PPV-VLPs by CsCl sedimentation analysis and
electron microscopy revealed identical properties to those of
native PPV virions. In some experiments, PPV-VLPs-OVA were
labeled with the fluorochrome Alexa 488, using the Alexa
Fluor™ 488 Protein Labeling Kit (Molecular Probes) according
to the manufacturer’s instructions.
The concentration of PPV-VLPs-OVA was determined by
densitometry and by double-antibody sandwich ELISA. The
densitometric assay was performed with 1D Image Analysis Soft-
ware 2.0.1 (Eastman Kodak Co.) using BSA as reference. The
double-antibody sandwich ELISA was performed as previously
described (26), using as capture antibody the anti-PPV mAb
15C5 and as detection antibody the anti-PPV biotinylated mAb
13C6 (27). Highly purified PPV-VLPs from size exclusion chro-
matography were used as standard reference. PPV-VLPs are
25-nM particles formed by 60 copies of VP2 (64 kD), and there-
fore the molecular mass of the particles is 3,840 kD.
Endotoxin values were determined in each sample of VLPs,
using the Limulus amebocyte lysate test (BioWhittaker Inc.). For
PPV-VLPs, endotoxin values were 
 
 
 
500 pg/mg of protein and
for PPV-VLPs-OVA, 
 
 
 
10 ng/mg.
 
Peptides and Cell Lines.
 
The OVA
 
257–264
 
 peptide (SIINFEKL)
that corresponds to an immunodominant H-2
 
b
 
–restricted CTL
epitope of OVA was purchased from Neosystem. B3Z, a CD8
 
  
 
T
cell hybridoma (28), specific for OVA
 
257–264
 
 epitope in the con-
text of K
 
b
 
, was a gift from N. Shastri (University of California,
Berkeley, CA). The thymoma EL-4 was obtained from American
Type Culture Collection.
 
Preparation of DCs and Other APCs.
 
Spleens from either nor-
mal or immunized mice were removed and treated for 45 min at
37
 
 
 
C with 400 U/ml collagenase type IV and 50 
 
 
 
g/ml DNase I
(Boehringer) in RPMI 1640. After inhibition of collagenase ac-
tivity with 6 mM EDTA in PBS, spleens were dissociated in
Ca
 
2
 
 
 
- and Mg
 
2
 
 
 
-free PBS in the presence of 2.5 mM EDTA and
0.5% FCS (GIBCO BRL) for in vitro and ex vivo assays or BSA
(Sigma-Aldrich) for immunization with DCs. In all assays involv-
ing DCs, the same lot of endotoxin-free FCS (as determined by
Limulus amebocyte lysate test) was used (batch 3013260S). All
solutions were also tested for endotoxins with the same test. Sin-
gle spleen cell suspensions were prepared and blocked with anti-
CD16/32 (2.4G2 clone; BD PharMingen) and with colloidal su-
per-paramagnetic microbeads, conjugated to anti-CD11c mAb
(magnetic-activated cell sorting [MACS]–anti-CD11c, N418
clone; Miltenyi Biotec), according to the manufacturer’s instruc-
tions. CD11c
 
  
 
cells were positively selected with high speed
MACS (AutoMACS; Miltenyi Biotec). The purified DC prepa-
rations contained 3–10% autofluorescent cells (defined as double
positive cells in a FL2 vs. FL3 dot plot without antibody labeling).
The purity of DC preparations (excluding autofluorescent cells)
was always 95–99%. CD11c
 
  
 
cells were H-2 K
 
b
 
 
 
, I-A
 
b low
 
,
CD40
 
low
 
, CD80
 
low
 
, and CD86
 
 
 
. 25–30% were CD8
 
 
 
  
 
and 60–
70% were CD8
 
 
 
  
 
CD11b
 
 
 
.
B220
 
  
 
spleen cells were obtained according to the same pro- 
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tocol (but without collagenase/DNase treatment) using rat
anti–mouse B220 mAb (MACS–anti-B220, clone RA3-6B2).
CD11b
 
  
 
CD11c
 
  
 
spleen cells were obtained from the CD11c
 
 
 
fraction after CD11c
 
  
 
cell purification by magnetic sorting. The
CD11c
 
  
 
cells were stained with anti–mouse CD11b mAb (Mac-
1
 
 
 
, MACS–anti-CD11b, clone M1/70) and purified with Au-
toMACS as well.
For the purification of CD8
 
 
 
  
 
and CD8
 
 
 
  
 
DCs or of
CD11b
 
high
 
 DCs, spleen cells were stained with MACS–anti-
CD11c, PE–anti-CD11c (HL-3 clone) and anti–CD16-32 anti-
bodies and FITC–anti-CD8  (53-6.7 clone) or FITC–anti-CD11b
(M1/70 clone; all three clones from BD PharMingen). After sort-
ing by AutoMACS, CD11c  cells were immediately sorted out in
a FACScan™ Plus (BD Biosciences) or in a MoFlo® (Cytoma-
tion, Inc.) cell sorter. Autofluorescent cells were gated out during
cell sorting. In all cases, the purity of both subpopulations was be-
tween 96–99%.
Antigen Presentation Assay. For in vitro assays, CD11c  spleen
cells (105 cells/well) were first pulsed with antigen (PPV-VLPs-
OVA, PPV-VLPs, or OVA257–264 peptide) for 4 h in 96-well cul-
ture microplates in a final volume of 0.2 ml of RPMI 1640
Glutamax-I, plus 5   10 5 M 2-ME, 100 IU/ml penicillin, 100
 g/ml streptomycin, and 10% FCS (10% RPMI; all from
GIBCO BRL). Subsequently, APCs were washed with 10%
RPMI and incubated overnight with 105 B3Z cells/well in a final
volume of 0.2 ml 10% RPMI at 37 C. The stimulation of B3Z
cells was monitored by IL-2 release in supernatants, which was
measured using the classic CTLL-2 bioassay. 104 cells/well of the
CTLL-2 cell line were cultured with 100- l supernatant in a final
volume of 0.2 ml. 2 d later, [3H]thymidine (ICN Biomedicals)
was added and the cells were harvested 6 h later with an auto-
mated cell harvester (Skatron). Incorporated thymidine was de-
tected by cell scintillation counting. All experiments were done
in duplicate. Results are expressed in counts per minute.
For ex vivo assays, PPV-VLPs-OVA or PPV-VLPs were in-
jected into the retro-orbital venous sinus of mice. APCs were iso-
lated and incubated with B3Z hybridoma overnight in the same
conditions as previously described.
CTL Assay. Spleen cells of immunized or control mice were
obtained 7 d after immunization and were stimulated in vitro for
5 d with 1  M OVA257–264 peptide in the presence of syngeneic
irradiated naive spleen cells. The cytotoxic activity of these effec-
tor cells was tested on 51Cr-labeled EL-4 target cells pulsed with
50  M OVA257–264 at different effector/target ratios. The released
radioactivity was measured in the supernatant. The percentage of
specific lysis was calculated as 100   (experimental release  
spontaneous release)/(maximum release   spontaneous release).
Maximum release was determined by adding 1% Triton X-100 to
EL-4 cells. Spontaneous release was obtained with target cells in-
cubated without effector cells. Nonpulsed EL-4 cells were used as
control of specificity.
Flow Cytometry. Cells were preincubated with a rat anti–
CD16/32 mAb (2.4G2 clone; BD PharMingen) for 15 min to
block unspecific binding of primary antibody and then stained
with the primary antibodies for 30 min. Cells were washed twice
and propidium iodide was added to label dead cells. A minimum
of 2   104 events were acquired for each sample on FACScan™
or FACSCalibur® cytometers and analyzed using CELLQuest™
software (all from BD Biosciences). The following mAbs were
used: anti-CD3  (145-2C11 clone), anti-CD4 (L3T4, RM4-5
clone), anti-CD8  (Ly-2, 53-6.7 clone), anti-CD8  (Ly-3.2, 53-
5.8 clone), anti-CD11b (Mac-1 , M1/70 clone), anti-CD11c
(HL-3 clone), anti-CD45R (B220, RA3-6B2 clone), anti-CD86
(B7.2, GL1 clone), and CD90 (Thy1.2, 30-H12), all purchased
from BD PharMingen. Anti-CD8  (CT-CD8a clone; Caltag)
and anti-CD205 (NLDC-145 clone; Cedarlane Laboratories
Ltd.) were also used.
Reverse Transcription (RT)-PCR. Total RNA was extracted
using RNA Plus solution (Quantum Appligene Société Anonyme),
from 5 10   105 purified DCs subpopulations (before or after
overnight culture). cDNA was synthesized from total RNA in
the presence of random primer p(dN)6 (Boehringer) using Molo-
ney murine leukemia virus reverse transcriptase SuperScript™
(GIBCO BRL). For all samples, synthesis of cDNA was con-
trolled by RT-PCR using  -actin primers for 30 cycles. CD8 
chain mRNA was analyzed using these primers: CAC GAA TAA
TAA GTA CGT TCT CAC C (sense) and ATG TAA ATA
TCA CAG GCG AAG TCC A (antisense). PCR were per-
formed using 1 IU of Goldstar DNA Taq polymerase (Advanced
Biotechnologies), 50 pmol of appropriate primers, 250  M of
each dNTP except for dCTP (3,000 Ci/mmol; NEN Life Sci-
ence Products) in 96-well polycarbonate Costar Thermowell™
strips (Corning) in a PTC-100™ programmable thermal control-
ler (MJ Research, Inc.). 40 cycles of amplifications were per-
formed as follows: 1 min at 94 C, 45 s at 48 C, 1 min at 72 C,
followed by 10 min of elongation at 72 C. Samples were sepa-
rated in 2% agarose gels and stained with ethidium bromide.
Results
In Vivo Induction of OVA257–264-specific Cytotoxic Response
by PPV-VLPs-OVA. In a previous report (19), we estab-
lished that PPV-VLPs carrying a CD8  T cell epitope of
LCMV (PPV-VLPs-LCMV) induced a strong LCMV-spe-
cific CTL response when injected without adjuvant. In the
present study, PPV-VLPs carrying an H-2b–restricted CD8 
T cell epitope from OVA257–264 (PPV-VLPs-OVA) were
used. We first tested the ability of PPV-VLPs-OVA to in-
duce a CTL response against OVA257–264 peptide–coated
cells. C57BL/6 mice were immunized intraperitoneally
with a single injection of 10  g PPV-VLPs-OVA or control
PPV-VLPs in PBS. As shown in Fig. 1 A, 7 d after immuni-
zation the mice immunized with PPV-VLPs-OVA devel-
oped a strong and specific CTL response against the
OVA257–264 epitope, whereas, as expected, mice injected
with control PPV-VLPs did not show a significant CTL re-
sponse. Similar CTL responses were obtained after two in-
traperitoneal injections (with a 21-d interval) or one intrave-
nous injection of PPV-VLPs-OVA (unpublished data). This
result confirmed our earlier demonstration of the high im-
munogenicity of PPV particles in the absence of adjuvant.
As previously demonstrated (19), the CTL response induced
by PPV-VLPs was MHC class I restricted and mediated by
CD8  T cells. Furthermore, inhibition by lactacystin and
N-acetyl-leucinyl-leucinyl-norleucinal of PPV-VLPs-OVA
presentation by purified DCs demonstrated that processing
PPV-VLPs-OVA requires proteasome (unpublished data).
These results confirm that PPV-VLPs can effectively deliver
an exogenous peptide into the MHC class I pathway.
In Vitro Processing of PPV-VLPs-OVA by DCs. DCs
have been clearly recognized as being the only APC capa-
ble of stimulating naive T cells. Therefore, we wondered1236 Presentation of Exogenous Particles by CD8   Dendritic Cells to CD8  T Cells
whether DCs could process PPV-VLPs-OVA and present
the OVA257–264–Kb complex to a specific hybridoma, as the
first step of CTL induction. Dendritic spleen cells were
highly purified from naive mice using the CD11c mole-
cule, which is considered the most generalized marker of
DCs, with  96% purity (Fig. 1 C). CD11c  cells were in-
cubated with PPV-VLPs-OVA, PPV-VLPs, or OVA257–264
peptide. The presence of OVA257–264–Kb complexes on
DCs was monitored by the stimulation of B3Z cells. DCs
incubated with PPV-VLPs-OVA or OVA257–264 peptide
efficiently presented the OVA257–264 epitope, whereas DCs
incubated with PPV-VLPs did not stimulate B3Z cells
(Fig. 1 B). Moreover, PPV-VLPs-OVA were highly effi-
cient in delivering the OVA257–264 epitope into the MHC
class I pathway, as compared in an equimolar ratio to the
OVA257–264 peptide (Fig. 1 B). CD11c  bone marrow–
derived DCs were also able to stimulate B3Z cells when
incubated with PPV-VLPs-OVA (unpublished data). There-
fore, DCs are able to process PPV-VLPs-OVA in vitro and
present the OVA257–264 epitope to MHC class I–restricted
T cells.
In Vivo Processing of PPV-VLPs-OVA by APCs. We
examined whether DCs can capture and process PPV-
VLPs in vivo using an ex vivo antigen-presenting assay.
C57BL/6 mice were intravenously injected with 50  g (13
pmol/mouse) PPV-VLPs-OVA or with PPV-VLPs. 90
min later, CD11c , CD11b  CD11c  (essentially mac-
rophages and granulocytes), and B220  cells (B cells) were
purified and cocultured with B3Z hybridoma. The purity
of B cells was always  99%, whereas that of CD11b 
CD11c  was  90% (Fig. 1 C). When incubated with B3Z
cells, only DCs purified from PPV-VLPs-OVA–injected
mice were able to present the OVA257–264 epitope, whereas
CD11b  CD11c  and B220  spleen cells were inefficient
(Fig. 1 D). The same APC populations purified from con-
trol PPV-VLPs–injected mice failed to stimulate B3Z cells,
although after overnight in vitro incubation with OVA257–264
peptide, they were fully able to stimulate B3Z cells (un-
published data). Thus, in vivo, DCs are the only APC ca-
pable of efficiently processing PPV-VLPs-OVA. DCs from
mice injected with 10  g (2.6 pmol/mouse) PPV-VLPs-
OVA can also present the OVA257–264 peptide, although to
a lower extent (unpublished data).
Cytosolic antigens have to be processed in the cytosol of
APCs and then transported to the Golgi complex to be
presented by MHC class I molecules. TAP molecules are
required as an essential step in this transport. Therefore, we
analyzed the ex vivo PPV-VLPs-OVA presentation by
DCs in TAP1 /  syngeneic mice. 90 min after PPV-VLPs-
OVA intravenous injection, spleen DCs from TAP1 / 
mice failed to present the OVA257–264 epitope, whereas
spleen DCs from TAP1 /  mice efficiently stimulated B3Z
cells (Fig. 1 E). Although TAP1 /  cells have a diminished
expression of class I MHC molecules (29), their capacity to
present peptide–Kb complexes was not essentially affected.
Indeed, TAP1 /  and TAP1 /  DCs incubated in vitro
with the OVA257–264 peptide equally presented this epitope
(unpublished data). Therefore, in vivo, the processing of
Figure 1. PPV-VLPs-OVA induce specific CTL responses and are pre-
sented in vitro and in vivo by DCs in a TAP-dependent way. (A)
C57BL/6 mice were intraperitoneally immunized with 10  g PPV-
VLPs-OVA ( ,  ) or 10  g control PPV-VLPs ( ,  ). 7 d later, their
spleen cells were stimulated in vitro with the OVA257–264 peptide and irra-
diated syngeneic cells for 5 d. Cytotoxic activity of the effector cells was
measured on 51Cr-labeled EL-4 cells loaded with the OVA257–264 peptide
( ,  ) or incubated with medium alone ( ,  ). Data are expressed as
mean   SEM of the percent lysis from two mice per group. One repre-
sentative experiment out of three is depicted. (B) CD11c  spleen cells
(105 cells/well) were incubated in vitro with PPV-VLPs-OVA ( ), con-
trol PPV-VLPs ( ), or OVA257–264 peptide ( ) for 4 h and then washed
and cultured overnight with 105 cells/well of B3Z cells. (C) Representa-
tive FACS® diagrams of purified CD11c  (left), CD11b  CD11c  (cen-
ter), or B220  (right) spleen cells. C57BL/6 mouse spleens were removed
and after collagenase/DNase I digestion cells were stained with MACS
beads–anti-CD11c or MACS beads–anti-B220 mAbs and passed through
a high speed magnetic-activated cell sorter (AutoMACS). The CD11c 
fraction was then labeled with MACS beads–anti-CD11b and resorted by
AutoMACS. (D) C57BL/6 mice were intravenously injected with 100
 g PPV-VLPs-OVA and 90 min later various numbers of CD11c  ( ),
CD11b  CD11c  ( ), and B220  ( ) cells purified from their spleens
were cocultured overnight with 105 B3Z cells/well. (E) TAP1 /  ( ) and
TAP1 /  ( ) C57BL/6 mice were intravenously injected with 100  g
PPV-VLPs-OVA and 90 min later CD11c  cells purified from their
spleens were cultured overnight at various cell numbers with 105 B3Z
cells/well. The presentation of OVA257–264 peptide to B3Z cells was mon-
itored by IL-2 production, measured by a CTLL proliferation assay, and
expressed as mean   SEM counts per minute (cpm) of duplicate wells.
One representative experiment out of three or four is depicted in each
case (two or three mice pooled per group).1237 Morón et al.
PPV-VLPs-OVA required TAP molecules, i.e., a cytosolic
processing in DCs.
Induction of CTL Response by DCs In Vivo Loaded with
PPV-VLPs-OVA. To establish whether DCs can induce
CTL response against the epitope delivered by PPV-VLPs,
naive syngeneic mice were immunized with CD11c ,
CD11b  CD11c , or B220  spleen cells purified from mice
intravenously injected with PPV-VLPs-OVA 90 min be-
fore purification. 7 d later, the CTL response against
OVA257–264-coated target cells was analyzed. As shown in
Fig. 2, only mice that received CD11c  cells, purified from
PPV-VLPs-OVA–injected mice, developed a CTL re-
sponse against the OVA257–264 epitope. In contrast, mice
that received CD11b  CD11c  or B220  cells purified
from the same mice did not develop such a specific CTL
response. Therefore, DCs are the only APC involved in the
in vivo induction of CTL response by PPV-VLPs-OVA.
Induction of CTL Response by PPV-VLPs-OVA Does Not
Require Cross-Priming. It is currently assumed that exoge-
nous antigens induce CTL response through the cross-
priming of DCs (1, 2) in a process that involves the transfer
of cell-associated antigens to DCs. Thus, we next deter-
mined whether cross-priming is involved in CTL activa-
tion by PPV-VLPs through the capture of PPV-VLPs asso-
ciated to cells by DCs.  2M /  and   2M /  C57BL/6
mice were intravenously injected with PPV-VLPs-OVA
and 90 min later their spleen DCs were purified. In vivo–
loaded DCs from both groups of mice were then injected
into syngeneic naive  2M /  mice and 1 wk later the
CTL response against OVA257–264 was analyzed (Fig. 3).
We reasoned that because  2M /  APCs are unable to
present MHC class I–restricted epitopes, a CTL response
against the OVA257–264 epitope could be induced only by
transfer of cell-associated antigens from  2M /  to  2M / 
DCs. Fig. 3 shows that CTLs against OVA257–264-coated
target cells were only observed after the injection of DCs
from  2M /  mice injected with PPV-VLPs-OVA, but
not after the administration of DCs purified from  2M / 
mice. These results clearly show that DCs capture exoge-
nous PPV-VLPs-OVA and directly induce CTL response,
and exclude that the observed CTL response is due to
cross-priming.
Processing of PPV-VLPs-OVA by Subpopulations of DCs.
In mice, spleen DCs do not constitute a homogeneous cell
population. On the basis of the CD8  chain expression, it
is now accepted that two major subsets of DCs can be dis-
tinguished: CD8   and CD8   DCs. To evaluate the ca-
pacity of these DC populations to process and present
PPV-VLPs, CD8   CD11c  and CD8   CD11c  cells
were purified. A two-step method was used: first, an en-
richment step of DCs by MACS anti-CD11c mAb and
then a fluorescent-activated cell sorting, using PE–anti-
CD11c and FITC–anti-CD8 . This proceeding allows the
recovery of a high number of purified DCs in a short time
with few steps and minimal manipulation. As shown in a
representative experiment (Fig. 4 A), the purity of both cell
populations was always  96%. Both DC subpopulations
were equally able to stimulate B3Z cells after in vitro incu-
bation with OVA257–264 peptide (Fig. 4 B, left), which
shows that CD8   and CD8   DCs have the same presen-
tation capacity. These two DC subpopulations were incu-
bated with PPV-VLPs-OVA and as shown in Fig. 4 B
(right), CD8    CD11c   cells effectively presented the
OVA257–264 epitope whereas CD8   CD11c  cells weakly
stimulated B3Z cells.
To see if a similar difference could also be observed in
vivo, we performed an ex vivo PPV-VLPs-OVA presenta-
tion assay. Mice were intravenously injected with 50  g
PPV-VLPs-OVA 90 min and 15 h before DC purification.
Splenic CD8   and CD8   DCs from both groups of
mice were simultaneously purified and incubated with
B3Z. When DCs were purified 90 min after injection, the
B3Z hybridoma was selectively stimulated by CD8  
DCs, whereas CD8   DCs had a weak stimulatory activ-
ity. In contrast, 15 h after injection, although CD8   DCs
were still able to stimulate B3Z cells, a very high stimula-
tion was observed with CD8   DCs (Fig. 4 C). Similar
results were obtained in 11 independent experiments con-
firming that CD8   DCs are capable of presenting PPV-
VLPs at early times, but 15 h later CD8   DCs are the
Figure 2. CD11c   spleen
cells, pulsed in vivo with PPV-
VLPs-OVA and injected into
naive mice, induce a CTL re-
sponse against OVA257–264 pep-
tide. C57BL/6 mice were intra-
venously injected with 10  g
PPV-VLPs-OVA ( ,  , and  )
or of control PPV-VLPs ( ). 90
min later, CD11c   ( ,   ),
CD11b  CD11c  ( ), and B220  ( ) spleen cells were purified and in-
travenously injected into naive syngeneic mice (1.5   105 cells/mice). 7 d
later, spleen cells from injected mice were stimulated in vitro with
OVA257–264 peptide for 5 d in the presence of irradiated syngeneic cells.
The cytotoxic activity of effector cells was measured on 51Cr-labeled EL-4
cells loaded with OVA257–264. In the inset the CTL activity on unloaded
51Cr-labeled EL-4 cells is shown. Data are expressed as the mean   SEM
of the percent lysis from duplicate samples of three mice per group. One
representative experiment out of three is represented.
Figure 3. DCs pulsed with
PPV-VLPs-OVA induce a CTL
response without the require-
ment of cross-priming.  2M / 
( ) and  2M /  ( ) C57BL/6
mice were intravenously injected
with 10  g PPV-VLPs-OVA,
whereas  2M /  C57BL/6 mice
were injected with PPV-VLPs as
control ( ). 90 min later,
CD11c  spleen cells were puri-
fied from each group and intravenously injected into  2M /  naive syn-
geneic mice (1.5   105 cells/mice). 7 d later, spleen cells from injected
mice were stimulated in vitro with the OVA257–264 peptide for 5 d in the
presence of irradiated syngeneic cells. The cytotoxic activity of effector
cells was measured on 51Cr-labeled EL-4 cells loaded with OVA257–264 or
incubated with medium alone. In the inset the CTL activity on unloaded
51Cr-labeled EL-4 cells is shown. Data are expressed as the mean   SEM
of the percent lysis from duplicate samples of two mice per group. One
representative experiment out of two is shown.1238 Presentation of Exogenous Particles by CD8   Dendritic Cells to CD8  T Cells
main DC subset capable of presenting this exogenous anti-
gen. Similar results were obtained with DCs from mice in-
jected with 10  g PPV-VLPs-OVA (unpublished data),
although the level of B3Z stimulation was lower. Interest-
ingly enough, under these sub-optimal conditions the pre-
sentation by CD8   DCs at 90 min was rather low com-
pared with the presentation of CD8   DCs at 15 h. Both
DC subpopulations, purified 90 min or 15 h after PPV-
VLPs-OVA injection and cultured overnight with the
OVA257–264 peptide (10 1 nM), efficiently stimulated B3Z
cells, which shows that these DCs retained the capacity to
present antigens at both assayed times (Fig. 4 C, insets).
Therefore, these two subpopulations seem to differ in their
capacity to take up/process PPV-VLPs, but not in their ca-
pacity to present the OVA257–264 epitope delivered by such
exogenous antigens.
PPV-VLPs Are Taken by DCs In Vivo. To characterize
the in vivo uptake of PPV-VLPs, we labeled PPV-VLPs-
OVA with Alexa 488, a strong green fluorescent dye that
fluorescence does not extinguish at low pH. After labeling,
Alexa 488–PPV-VLPs-OVA maintained their capacity to
be processed and presented by DCs to B3Z cells (unpub-
lished data), showing the preservation of their biological
activity. We injected Alexa 488–PPV-VLPs-OVA into na-
ive C57BL/6 mice. 90 min later, their spleen cells were
sorted out into CD11c , CD11b , and B220  subpopula-
tions by magnetic sorting and were labeled with several
mAbs. A representative experiment is depicted in Fig. 5 A
and summarized in Fig. 5 B. 90 min after injection, only a
small fraction of B220  spleen cells captured Alexa 488–
PPV-VLPs-OVA (Fig. 5 A, a). In contrast, half of the
CD11c  cells were Alexa 488  (Fig. 5 A, b). When CD11b 
cells were isolated and labeled with an anti-CD11c anti-
body, these two main cell populations were evidenced: one
that was strongly Alexa 488  CD11c  and another that was
Alexa 488low CD11c  (Fig. 5 A, c). These results demon-
strated that in the pool of CD11b  cells, PPV-VLPs are
mainly captured by CD11c  cells (i.e., DCs). Granulocytes,
labeled with anti-GR1 mAb, did not show any uptake of
Alexa 488–PPV-VLPs-OVA (unpublished data), which
suggests that the weak uptake observed in the CD11c 
CD11b  population could be attributed to spleen mac-
rophages. 15 h after injection, DCs remained strongly posi-
tive for Alexa 488, whereas B cells were still negative and
macrophages were weakly positive for fluorescent VLPs
(unpublished data).
Figure 4. Differential kinetics of in vivo PPV-VLPs-
OVA presentation by CD8   and CD8   DCs. (A)
Purification of CD8   and CD8   CD11c  spleen
cells. Spleens from C57BL/6 mice were removed and
after collagenase/DNase I digestion, cells were stained
with MACS beads–anti-CD11c, PE–anti-CD11c, and
FITC–anti-CD8  antibodies and passed through an Au-
toMACS and then immediately through a FACScan™
or MOFLO®. The percentages of the different cell
populations obtained after each step of purification are
indicated and correspond to naive mice. (B) In vitro
antigen presentation assays. Spleen CD8   ( ) and
CD8   ( ) CD11c  cells were incubated in vitro with
OVA257–264 peptide (left) or PPV-VLPs-OVA (right)
for 4 h. They were then washed and cultured over-
night with 105 B3Z cells/well. (C) Ex vivo PPV-VLPs-
OVA presentation assays. Mice were intravenously in-
jected with 50  g PPV-VLPs-OVA at 90 min (left) or
15 h (right) before DC purification. CD8   ( ) and
CD8    ( ) CD11c   cells as well as CD11c   ( )
spleen cells were purified and cultured overnight with
105  B3Z cells/well. In the insets, CD8   ( ) and
CD8   ( ) CD11c  cells purified from PPV-VLPs-
OVA–injected mice were cultured overnight with 105
B3Z cells/well in the presence of 10 1 nM OVA257–264
peptide. The presentation of the SIINFEKL peptide to
B3Z cells was monitored by IL-2 production, mea-
sured by a CTLL proliferation assay, and expressed as
mean   SEM counts per minute (cpm) of duplicate
wells. One representative experiment out of two (for
B) or seven (for C) is depicted (three to five pooled
mice per group).1239 Morón et al.
Considering the different capacity of CD8   and CD8  
DCs to present PPV-VLPs-OVA, we investigated whether
a differential uptake of PPV-VLPs-OVA by these two DC
populations exists. Mice were injected with Alexa 488–
PPV-VLPs-OVA and 90 min or 15 h later their spleen DCs
were purified and labeled with anti-CD8  and anti-CD4
mAbs to distinguish the three main spleen DC subpopula-
tions: CD4  CD8  , CD4  CD8  , and CD4  CD8  
DCs (Fig. 6 A). 90 min after Alexa 488–PPV-VLPs-OVA
injection, all DC subpopulations in the spleen captured
PPV-VLPs and kept the fluorescence for at least 15 h (Fig. 6
B). However, CD4  CD8   DCs took slightly more PPV-
VLPs than CD8   DCs. Furthermore, 15 h later we ob-
served a decrease in the percentage and mean fluorescence
intensity FL1 of Alexa 488  CD4  CD8   DCs (Fig. 6 C),
which was not observed with other DC subpopulations.
This decrease correlated with a diminution in the propor-
tion of this subpopulation in the whole spleen DC pool.
In conclusion, although CD8   DCs were unable to
present PPV-VLPs-OVA 90 min after injection, they had
already captured them. These results demonstrate that the
differences observed in PPV-VLPs-OVA presentation be-
tween CD8   and CD8   DCs could not be attributed to
a difference in the uptake of PPV-VLPs-OVA.
CD8   CD11b  CD11c  Cells, In Vivo Pulsed with
PPV-VLPs-OVA, Express the CD8  Molecule, Up-regulate
CD205 and Down-regulate CD4 in Rag2 /  but Not in
Rag2 /  Mice. Considering the different capacity of DC
subpopulations to present epitopes delivered by PPV-VLPs
at different times, and the decrease of the proportion of
CD4  CD8   DCs observed 15 h after the uptake of Alexa
488–PPV-VLPs-OVA, we analyzed whether these differ-
ences could be related to changes in the composition of
spleen DC populations. Therefore, we injected 50  g
PPV-VLPs to Rag2 /  mice and 15 h later we recovered
the CD11c  spleen cells for FACS® analysis. After PPV-
VLPs injection, no major changes were observed in the
percentages of DC subpopulations in a CD11c versus
CD8  dot plot, except for a little shift toward the right of
the CD8   subpopulation (Fig. 7 A). However, when
CD8  expression was analyzed against CD11b expression
in CD11c  cells, a significant number of CD11b  cells ex-
pressed CD8   after PPV-VLPs injection. Furthermore,
these CD8   CD11b  CD11c  cells represented an impor-
tant percentage of total CD8   DCs (Table I). The same
analysis performed with another anti-CD8   antibody
showed similar results (Fig. 7 A). This CD8   CD11b 
DC population was observed until 24 h after PPV-VLPs
injection and then disappeared (unpublished data). One
possible explanation for this result could be that CD8  T
cells interacting with DCs remained attached after sorting,
giving a false CD8  staining on DCs. However, anti-CD90
antibody (unpublished data) as well as an anti-CD8  anti-
body did not label DCs (Fig. 7 A), making this hypothesis
unlikely. At the same time a strong decrease in the percent-
age of CD4  CD11b  DCs was observed. This modifica-
tion was accompanied by a diminution in the intensity of
CD4 expression. Furthermore, the expression of CD205
was up-regulated after PPV-VLPs injection in CD11b 
DCs. The same analysis performed 90 min after PPV-
VLPs-OVA injection showed no change in the expression
of CD8 , CD4, or CD205 on CD11b  or CD11b  DCs
compared with noninjected mice (unpublished data).
These phenotypic changes were accompanied by the up-
regulation or expression of several molecules related to the
maturation of DCs, such as CD86 (Fig. 7 A), MHC class I
and II, CD40, and CD80 (unpublished data) molecules.
The injection of 5 and 25  g (1.3 and 6.5 pmol, respec-
Figure 5. PPV-VLPs-OVA are uptaken in vivo by DCs. (A) One
C57BL/6 mouse was intravenously injected with 50  g Alexa 488–PPV-
VLPs. One PBS-injected mouse was used as a control. 90 min later, their
spleen cells were obtained and sorted out into B220  (a), CD11c  (b), or
CD11b  (c) subpopulations by magnetic sorting. All cell populations ob-
tained were then stained with PE–anti-B220, PE–anti-CD11b, and PE–
anti-CD11c and analyzed on a FACStar™ cytometer. Dot plot analysis of
B220  (a), CD11c  (b), and CD11b  (c) cells purified from PPV-VLPs–
injected or control mice and labeled with the indicated PE-coupled mAbs
are shown. B220  cells were negative for CD11c and CD11b. (B) The
percentage and mean fluorescence intensity of Alexa 488   cells in
CD11c , CD11b , and B220  cells in the spleen of Alexa 488–PPV-
VLPs-OVA–injected mice, as detailed in A. One representative experi-
ment out of two is depicted.1240 Presentation of Exogenous Particles by CD8   Dendritic Cells to CD8  T Cells
tively) PPV-VLPs induced similar changes, although to a
lower extent (unpublished data).
To examine whether T cells play a role in these events,
we repeated these experiments using Rag2 /  mice. In
Rag2 /  mice, CD11b  DCs showed no expression of
CD8 , but there was a decrease in the percentage of
CD8   CD11b  DCs after PPV-VLPs injection (Fig. 7
A and Table I). The percentage of CD4  DCs was only
slightly decreased whereas the expression of CD205
showed a small increase. However, CD8   and CD8  
DCs from Rag /  mice showed an up-regulation of CD86
(Fig. 7 A) and MHC class I and II, CD40, and CD80 mol-
ecules (unpublished data) showed that they are indeed tar-
geted by PPV-VLPs. The capture of Alexa 488–PPV-
VLPs-OVA by CD4  CD8  , CD4  CD8  , and CD4 
CD8   DCs from Rag /  mice, 90 min and 15 h after in-
jection, was comparable to that observed with normal mice
(unpublished data).
The expression of the CD8  molecule could be attrib-
uted to these two different origins: the translation of CD8 
mRNA by CD11b  DCs or the uptake of CD8  mole-
cules from other cells, such as CD8  T cells or CD8  
CD11b  DCs. To address this question, we analyzed the
expression of CD8  mRNA by two rounds of RT-PCR
Figure 6. In vivo uptake of PPV-
VLPs by DC subpopulations.
C57BL/6 mice were intravenously
injected with 50  g Alexa 488–
PPV-VLPs-OVA. 90 min or 15 h
later their CD11c  spleen cells were
purified and stained with PE and
APC-coupled mAbs for analysis on a
FACScalibur®  cytometer. Nonin-
jected mice were used as control.
(A) CD11c  spleen cells from con-
trol mice were stained with APC–
anti-CD8   and either PE–anti-
CD11c (left) or PE–anti-CD4
(right). In this representative experi-
ment, CD11c  purified spleen cells
contained 53% CD4  CD8  , 17%
CD4   CD8  , and 20% CD4 
CD8  . Similar values were ob-
tained from injected mice. (B) FL1
(Alexa 488) histograms, gated on re-
gions marked on the right panel in A, corresponding to CD4  CD8  , CD4  CD8  , and CD4  CD8   CD11c  cells purified 90 min (thick line his-
tograms) or 15 h (gray histograms) after injection or from control (thin line histograms). (C) Percentage and mean fluorescence intensity of Alexa 488 
cells, corresponding to the histograms depicted in B. One representative experiment out of two is depicted.
Figure 7. CD11b   DCs from
Rag2 /   but not from Rag2 / 
mice express CD8 , up-regulate
CD205, and down-regulate CD4
molecules after PPV-VLPs injec-
tion. (A) C57BL/6 Rag2 /   or
Rag2 /  mice were intravenously
injected with 50  g PPV-VLPs.
Noninjected mice from each strain
were used as a control. 15 h later,
CD11c  spleen cells were purified
and stained with anti-CD11b and
anti-CD8  antibodies plus one of
the following antibodies: anti-
CD11c, anti-CD4, anti-CD205,
anti-CD8 , or anti-CD86. Cells
were analyzed on a FACScalibur®
cytometer. One representative ex-
periment out of two (for Rag2 / )
or three (for Rag2 / ) is depicted.
(B) Expression of CD8  mRNA
by DC subsets. Mice were injected
with PPV-VLPs and 90 min later,
CD8   CD11c  spleen cells were
purified and cultured for 15 h (Exp.
1) or for different times (0, 3, 5, 8,
and 15 h, Exp. 2). Then, the mRNA was extracted for RT-PCR (two rounds of 40 cycles per round) using primers for CD8 . mRNA from
CD8   DCs purified 90 min after injection was used as a positive control.1241 Morón et al.
(40 cycles/round) of spleen DC subsets purified 90 min af-
ter PPV-VLPs injection and cultivated for different times
(0, 3, 5, 8, and 15 h). CD8  mRNA was found only in
CD8   CD11b  DCs but not in CD11b  DCs (Fig. 7 B),
which shows that CD8  molecules present at the surface of
CD11b  DCs after PPV-VLPs injection did not come from
de novo synthesis of this molecule.
Comparable Presentation of the OVA257–264 Epitope by
CD11bhigh DCs 90 min and 15 h after Injection of PPV-VLPs-
OVA. Because some CD11b  DCs express the CD8 
molecule 15 h after PPV-VLPs injection, we analyzed the
presentation of the OVA257–264 epitope by these CD8  
CD11b   DCs. Because DCs express variable levels of
CD11b, it is difficult to define clear-cut subpopulations based
on this marker. Therefore, only CD11bhigh DCs were puri-
fied from mice injected with PPV-VLPs-OVA 90 min or
15 h earlier (CD11blow DCs always contained both CD8  
and CD8   cells). CD11bhigh DCs did not express CD8  90
min after PPV-VLPs-OVA injection, but they expressed this
molecule 15 h later (Fig. 8 A). Moreover, CD11bhigh were
able to present the OVA257–264 epitope 90 min as well as 15 h
after PPV-VLPs-OVA injection (Fig. 8 B). These results
show that the CD11b  DCs that acquired the CD8  mole-
cule were able to present the OVA257–264 epitope.
Presentation of the OVA257–264 Epitope by CD8   and
CD8   DCs from Rag /  Mice. Because we did not de-
tect the phenotypic changes in Rag /  mice injected with
PPV-VLPs that we observed in Rag /  mice, we ana-
lyzed the OVA257–264 epitope presentation by CD8   and
CD8   DCs from Rag /  mice 90 min and 15 h after
PPV-VLPs-OVA injection. 90 min after PPV-VLPs-OVA
injection, CD8   DCs from Rag /  and Rag /  mice
were unable to present the OVA257–264 epitope, whereas
CD8   DCs from both strains stimulated the B3Z hybrid-
oma. When the antigen presentation was performed 15 h
after PPV-VLPs-OVA injection, the CD8   DCs from
both strains presented the OVA257–264 epitope with an effi-
cacy comparable to the stimulation obtained 90 min after
injection (Fig. 8 C). In contrast, CD8   DCs from Rag / 
mice strongly stimulated B3Z cells whereas CD8   DCs
from Rag /  mice did not exhibit such a dramatic increase
in their capacity to stimulate B3Z cells and presented the
OVA257–264  epitope with an efficacy similar to CD8  
DCs. These results could suggest that T cells are required
for CD8   DCs to present the OVA257–264 epitope. Thus,
to verify this hypothesis we transferred CD90  cells
(98% T cells, 43% CD4 , 33% CD8 , B220 , CD11b ,
CD45RB , and CD69 ; data not shown) purified from
Rag /  mice to naive Rag /  mice. 2 d later, we intrave-
nously injected PPV-VLPs-OVA to these mice and then
tested the ability of CD8   and CD8   DCs to present the
OVA257–264 epitope 15 h after injection. Surprisingly, under
these conditions, neither CD8   nor CD8   DCs were
able to stimulate B3Z cells (unpublished data).
Discussion
VLPs clearly demonstrated their potential as vector for
vaccination (3, 16–19, 21, 30) and have proven to be a po-
Table I. CD11b  DCs Express CD8  in Rag2 /  Mice Injected 
with PPV-VLPs-OVA
CD11b  CD8   cells
percentage in total
CD8   DCs
CD11b  CD8   cells
percentage in total
CD11b  DCs
Rag2 / 
mice
Rag2 / 
mice
Rag2 / 
mice
Rag2 / 
mice
Injection of
PPV-VLPs         
Exp. 1 19 43 5 12 7 15 4 4
Exp. 2 30 45 17 28 11 23 9 11
Exp. 3 ND ND 19 22 ND ND 9 8
C57BL/6 Rag2 /  or Rag2 /  mice were intravenously injected with
50  m PPV-VLPs. Noninjected mice from each strain were used as a
control. 15 h later, CD11c  spleen cells were labeled with CD11b and
anti-CD8  antibodies and analyzed on a FACScalibur® cytometer. At
least 2   104 events were analyzed.
Figure 8. CD11b  DCs present the OVA257–264 epitope 90 min as well
as 15 h after the injection of PPV-VLPs-OVA. Mice were intravenously
injected with 50  g PPV-VLPs-OVA and 90 min or 15 h later,
CD11bhigh CD11c  spleen cells were purified by AutoMACS and a
MOFLO® cell sorter. (A) Dot plot analysis of CD11bhigh DCs stained
with an anti-CD8  antibody after sorting. (B) Splenic CD11c  ( ) and
CD11bhigh CD11c  cells purified 90 min ( ) or 15 h ( ) after PPV-
VLPs-OVA injection were cultured overnight with 105 B3Z cells/well.
(C) Ex vivo PPV-VLPs-OVA presentation by DC subsets in Rag / 
mice. Naive Rag /  ( ,  ) or Rag /  ( ,  ) mice were intravenously
injected with 50  g PPV-VLPs-OVA, 90 min (left) or 15 h (right) before
DC purification. CD8   ( ,  ) and CD8   ( ,  ) CD11c  as well as
CD11c  ( ) cells were simultaneously purified from these mice and
cultured overnight with 105 B3Z cells/well. The presentation of the
SIINFEKL peptide to B3Z cells was monitored by IL-2 production,
measured by a CTLL proliferation assay, and expressed as mean   SEM
counts per minute (cpm) of duplicate wells. One representative experi-
ment out of two is presented (three pooled mice per group).1242 Presentation of Exogenous Particles by CD8   Dendritic Cells to CD8  T Cells
tent CTL inducer when compared with other vectors (31).
We have developed a VLPs system from PPV that has
shown a powerful capacity to elicit both CD4  (32) and
CD8  (19, 25, 33) T cell responses in the absence of any
adjuvant. In this study, we analyzed the in vivo processing
and presentation of PPV-VLPs carrying a CD8  T cell
epitope. In vitro, PPV-VLPs-OVA were as efficient as the
synthetic OVA257–264 peptide in stimulating specific T cell
hybridoma. In vivo, after intravenous injection of PPV-
VLPs-OVA, only DCs were capable of presenting the
OVA257–264 epitope to CD8  T cells. Additional experi-
ments revealed that PPV-VLPs were efficiently captured by
DCs. Finally, only DCs purified from PPV-VLPs-OVA–
injected mice could elicit a CTL response. These data
clearly demonstrate that in vivo, processing and presenta-
tion of PPV-VLPs are performed by DCs.
Several mechanisms responsible for the processing of ex-
ogenous antigens in the MHC class I pathway have been
described (34). Some are TAP- and proteasome-indepen-
dent pathways, based on the regurgitation of antigen (35)
or the recycling of MHC class I molecules (36) in which
antigens are most likely degraded in endosomes and bind to
MHC class I molecules without transfer to the cytosol. An
alternative pathway, TAP and proteasome dependent, in-
volves the transfer of antigens from phagosomes/macropi-
nosomes to the cytosol, processing by the proteasome
complex, and translocation into endoplasmic reticulum/
Golgi network using TAP molecules, following the classic
MHC class I pathway (37). This last pathway has been
shown to be much more efficient than the TAP-indepen-
dent pathways (38). Some antigens could generate CTL re-
sponse using simultaneously multiple MHC class I process-
ing pathways (39). In the present study, we demonstrated
that although PPV-VLPs are exogenous antigens, they en-
ter into the MHC class I pathway, gain access to cytosol,
and are processed by a classic pathway as evidenced by the
absence of stimulation of hybridoma cells by PPV-VLPs-
OVA–pulsed DCs from TAP1 /  mice and by the require-
ment for proteasome processing (unpublished data).
Bohm et al. (16) have reported that hepatitis B surface
antigen particles are processed by macrophages as well as
DCs and that both cell types can prime a CTL response in
vivo. However, the processing pathway of these VLPs are
clearly different from that of PPV-VLPs. Hepatitis B sur-
face antigen particles bind to recycling rather than new
synthesized MHC class I molecules (40). In contrast, PPV-
VLPs–derived peptides bind to new, nascent MHC class I
molecules, as evidenced by the absence of PPV-VLPs-
OVA presentation in TAP /  mice. DCs, but not mac-
rophages, have the ability to transport the antigens from
endosomes to cytosol and then use the cytosolic machinery
of processing (41). This may explain why PPV-VLPs,
which need cytosolic processing, can only be presented by
DCs in vivo.
Cross-priming, a process first described by Bevan (1, 2;
for review see reference 42), allows exogenous antigens to
elicit a CTL response. The TAP transporter is required for
in vivo cross-priming of MHC class I–restricted antigens
(43). Hence, considering that PPV-VLPs processing is TAP
dependent, we analyzed whether the CTL response in-
duced by PPV-VLPs-OVA is mediated by cross-priming or
by direct priming, i.e., by the DC that capture PPV-VLPs-
OVA. The transfer of  2M /  DCs from PPV-VLPs-
OVA–injected mice to naive  2M /  mice did not induce
a CTL response, whereas the PPV-VLPs-OVA–pulsed
 2M /  DCs induced such a response. This result clearly
shows that DCs initially targeted by PPV-VLPs-OVA are
the APCs that induce the CTL response. It should also be
noted that the CTL response induced by PPV-VLPs is
CD4 independent (19), whereas so far, the CTL responses
induced by cross-priming are described to be CD4 depen-
dent (42, 44). Therefore, our data demonstrate that DCs
capture exogenous PPV-VLPs-OVA and are able to di-
rectly induce a CTL response without cross-priming.
The role of dendritic subsets in the induction of T cell
responses is still a matter of intense debate. It has been
shown that in mice, splenic CD8   DCs have the ability to
produce large amounts of IL-12 and preferentially induce
Th1 responses. By contrast, CD8   DCs do not produce
large amounts of IL-12 and preferentially induce Th2 re-
sponses (45, 46). However, polarization depends upon the
site of injection, because the intravenous injection of
CD8   or CD8   DCs pulsed with peptide induces non-
polarized Th response (47). Concerning the induction of
CTL response, one recent study (15) reported that only
CD8   but not CD8   DCs from mice injected with
OVA-loaded splenocytes can cross-prime CD8  T cells, al-
though both DC subsets were shown to capture the same
amounts of antigen. They suggested that this differential
ability could be associated with a different in vivo process-
ing due to a selective capacity of CD8   DCs to transport
antigen from the endosome to cytosol. Pooley et al. (48)
also found that CD8   DCs were the principal APC 18 h
after an intravenous injection of a high amount of OVA
protein. The injection of mice with peptide-pulsed
CD8   and CD8   DCs has clearly demonstrated that
both DC subsets are equally able to induce a CTL response
(47, 49).
In this study we have shown that all DC subsets can cap-
ture Alexa 488–PPV-VLPs-OVA to a similar extent, al-
though CD8   DCs showed a little higher mean fluores-
cence intensity than CD8    DC populations, perhaps
because they are slightly larger than CD8   DCs (49).
However, we also showed that shortly after PPV-VLPs-
OVA injection, only CD8   DCs are responsible for the
OVA257–264 epitope presentation whereas 15 h later, the
presentation is mainly performed by CD8   DCs. Thus,
these results demonstrated that CD8   DCs have the ca-
pacity to present the OVA257–264 epitope very early after
PPV-VLPs capture, whereas CD8   DCs presented the
OVA257–264 epitope only after a lag time. Because PPV-
VLPs are captured efficiently by both subsets, the difference
in the accessibility of PPV-VLPs to DCs cannot explain
these results. Interestingly, CD8   from Rag /  and Rag / 
mice exhibited, at 90 min as well as at 15 h, comparable ef-
ficacy to capture and present PPV-VLPs-OVA, which1243 Morón et al.
shows that the processing by this DC subset is T cell inde-
pendent. In contrast, 15 h after PPV-VLPs-OVA injection,
CD8   DCs from Rag /  mice were unable to present the
OVA257–264 epitope with the high efficacy of CD8   DCs
from Rag /  mice. This could suggest that T cells play a
role in the licensing of CD8   DCs for exogenous antigen
presentation. Therefore, our results could suggest that
CD8   and CD8   DCs have differential requirements for
MHC class I–restricted presentation of exogenous antigens.
Using two different anti-CD8  antibodies, we demon-
strated that 15 h after the injection of PPV-VLPs, a signifi-
cant percentage of CD11b  DCs expressed CD8 . These
cells also expressed CD205. Moreover, the proportion of
CD4  CD8   DCs showed an important decrease at that
time, associated with a diminution in the intensity of ex-
pression of the CD4 molecule on those cells. Our study is
the first in vivo report showing the apparition of a CD8  
and CD205  CD11b  DC population in the spleen after
the injection of an antigen. A very recent report suggests
that CD8   DCs could originate from the CD8   DC
subset by a maturation process involving CD8 , DEC-205,
and CD24 up-regulation 18 h after CD8   DC transfer
(50). However, in that study, the phenotypic change was
observed after cell transfer without any stimulation,
whereas in our case it was induced by the injection of an
antigen. An association of some T cells with DCs, which
could eventually explains our results, is excluded because:
(a) all purification steps included EDTA, which disrupts in-
teractions between cells, (b) no CD8  mRNA was de-
tected in sorted CD8   DCs, and (c) anti-CD3 , anti-
CD8 , and anti-CD90 antibodies did not specifically
bind to purified CD11b   DCs. A population of
CD11bdullCD11c  that expressed CD8  in mice treated
with Flt3L was described in two previous reports (51, 52).
However, in this study the CD8   population is CD11b ,
indicating that these populations are different.
The absence of CD8  mRNA in CD11b  DCs har-
vested at various times after PPV-VLPs injection suggests
that CD8  expression on these cells is not due to de novo
synthesis. The lack of expression of the CD8  molecule on
CD11b  DCs from Rag2 /  mice injected with PPV-
VLPs, as well as the slight reduction in CD4 expression and
the small increase of CD205, also suggests that T cells may
play a role in these phenotypic changes. Indeed, the similar
uptake of Alexa 488–PPV-VLPs-OVA in Rag /   and
Rag /  mice (unpublished data), as well as the up-regula-
tion of CD86 in DCs of Rag /  mice, excluded the possi-
bility that these effects were due to a lack of accessibility of
VLPs to DCs from Rag /  mice. It remains to be deter-
mined if the dramatic increase of CD8   presentation ob-
served 15 h after PPV-VLPs-OVA injection was due to the
CD11b  CD8   or to the CD11b  CD8   population,
which was inefficient at 90 min and therefore required
longer times than CD8   DCs for VLPs processing.
This study clearly demonstrates that CD8   DCs have
the capacity to transfer the VLPs to the cytosolic pathway
and present these exogenous antigens without cross-prim-
ing almost immediately after antigen uptake and indepen-
dently of T cells. In contrast, CD8   DCs cannot present
PPV-VLPs immediately after capture, but exhibited a very
strong capacity to present the OVA257–264 epitope carried
by VLPs at longer times after VLPs capture. The fact that in
Rag /  mice the lack of expression of CD8  by CD11b 
DCs was accompanied by the inability of CD8   DCs to
acquire the same antigen-presenting capacity than in Rag / 
mice suggests that both events are closely linked.
In conclusion, this study highlighted the specialization
of the various DC subsets. Our results, which show that
CD8   DCs can acquire molecules such as CD8   and
CD205 after activation, strongly support the view that in
vivo studies addressing the functions of DC subsets must
define DC subsets carefully, based on the analysis of vari-
ous markers.
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